Bank of America’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-128
| Closed | -$203 | – | 6555 |
|
|
2025
Q4 | $203 | Sell |
128
-90,347
| -100% | -$144K | ﹤0.01% | 6697 |
|
|
2025
Q3 | $95.9K | Buy |
90,475
+82,662
| +1,058% | +$143K | ﹤0.01% | 6614 |
|
|
2025
Q2 | $12.5K | Sell |
7,813
-2,177
| -22% | -$3.47K | ﹤0.01% | 7149 |
|
|
2025
Q1 | $12.2K | Sell |
9,990
-9,435
| -49% | -$16.5K | ﹤0.01% | 7083 |
|
|
2024
Q4 | $36.7K | Buy |
19,425
+4,291
| +28% | +$17.7K | ﹤0.01% | 6710 |
|
|
2024
Q3 | $80.8K | Buy |
15,134
+1,420
| +10% | +$10.4K | ﹤0.01% | 6411 |
|
|
2024
Q2 | $101K | Sell |
13,714
-44,268
| -76% | -$355K | ﹤0.01% | 6250 |
|
|
2024
Q1 | $692K | Buy |
57,982
+47,180
| +437% | +$381K | ﹤0.01% | 5153 |
|
|
2023
Q4 | $85.1K | Buy |
10,802
+5,626
| +109% | +$47.6K | ﹤0.01% | 6436 |
|
|
2023
Q3 | $22.9K | Buy |
5,176
+1,903
| +58% | +$42.1K | ﹤0.01% | 6690 |
|
|
2023
Q2 | $114K | Sell |
3,273
-3,101
| -49% | -$84.5K | ﹤0.01% | 6145 |
|
|
2023
Q1 | $139K | Sell |
6,374
-1,045
| -14% | -$23.4K | ﹤0.01% | 6114 |
|
|
2022
Q4 | $160K | Buy |
7,419
+2,768
| +60% | +$60.2K | ﹤0.01% | 6027 |
|
|
2022
Q3 | $113K | Buy |
4,651
+44
| +1% | +$1.02K | ﹤0.01% | 6282 |
|
|
2022
Q2 | $94K | Sell |
4,607
-1,362
| -23% | -$39.2K | ﹤0.01% | 6517 |
|
|
2022
Q1 | $212K | Sell |
5,969
-93
| -2% | -$2.9K | ﹤0.01% | 6427 |
|
|
2021
Q4 | $165K | Buy |
6,062
+5,820
| +2,405% | +$208K | ﹤0.01% | 6602 |
|
|
2021
Q3 | $11K | Buy |
242
+240
| +12,000% | +$11.6K | ﹤0.01% | 7549 |
|
|
2021
Q2 | $0 | Sell |
2
-498
| -100% | -$23.1K | ﹤0.01% | 7990 |
|
|
2021
Q1 | $22K | Hold |
500
| – | – | ﹤0.01% | 6862 |
|
|
2020
Q4 | $13K | Buy |
500
+340
| +213% | +$7.11K | ﹤0.01% | 6673 |
|
|
2020
Q3 | $2K | Buy |
+160
| New | +$3.57K | ﹤0.01% | 6704 |
|
|
2020
Q1 | – | Sell |
-177
| Closed | -$2K | – | 7131 |
|
|
2019
Q4 | $2K | Buy |
+177
| New | +$4.12K | ﹤0.01% | 6895 |
|
|
2019
Q2 | – | Sell |
-64
| Closed | -$10K | – | 7346 |
|
|
2019
Q1 | $10K | Hold |
64
| – | – | ﹤0.01% | 6657 |
|
|
2018
Q4 | $5K | Sell |
64
-14
| -18% | -$1.72K | ﹤0.01% | 6768 |
|
|
2018
Q3 | $12K | Buy |
78
+15
| +24% | +$2.11K | ﹤0.01% | 6630 |
|
|
2018
Q2 | $8K | Hold |
63
| – | – | ﹤0.01% | 6709 |
|
|
2018
Q1 | $9K | Sell |
63
-197
| -76% | -$35.2K | ﹤0.01% | 6638 |
|
|
2017
Q4 | $54K | Buy |
260
+197
| +313% | +$40.8K | ﹤0.01% | 6035 |
|
|
2017
Q3 | $14K | Buy |
+63
| New | +$11.5K | ﹤0.01% | 6424 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7166 |
|
|
2016
Q4 | – | Sell |
-122
| Closed | -$68.3K | – | 7229 |
|
|
2016
Q3 | $83K | Buy |
+122
| New | +$77.5K | ﹤0.01% | 5512 |
|
Other funds holding OTLK
AC
VCM
GWM
WAM
NMC
CCM
Bank of America's OTLK Position: Q1 2026 in Review
Bank of America sold out of Outlook Therapeutics (OTLK) in Q1 2026, closing a stake of 128 shares — an estimated $203 sold.
Bank of America first reported a position in OTLK in Q3 2016 and held it in 31 quarters. The position peaked at $692K in Q1 2024. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.
- Bank of America reported no remaining Outlook Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 128 Outlook Therapeutics shares in Q1 2026, an estimated $203.
- Bank of America first reported a position in Outlook Therapeutics in Q3 2016 and held it in 31 quarters.
- Bank of America's Outlook Therapeutics position peaked at $692K in Q1 2024.
- 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.